Amedeo Smart

Free Medical Literature Service


 

Amedeo

Vaccines

  Free Subscription

Articles published in
PLoS Med
    May 2023
  1. KUMAR CK, Sands K, Walsh TR, O'Brien S, et al
    Global, regional, and national estimates of the impact of a maternal Klebsiella pneumoniae vaccine: A Bayesian modeling analysis.
    PLoS Med. 2023;20:e1004239.
    >> Share

    March 2023
  2. MEMIRIE ST, Tolla MT, Rumpler E, Sato R, et al
    Out-of-pocket expenditures and financial risks associated with treatment of vaccine-preventable diseases in Ethiopia: A cross-sectional costing analysis.
    PLoS Med. 2023;20:e1004198.
    >> Share

    February 2023
  3. NORDSTROM P, Ballin M, Nordstrom A
    Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden.
    PLoS Med. 2023;20:e1004127.
    >> Share

    January 2023
  4. DIMITROVA A, Carrasco-Escobar G, Richardson R, Benmarhnia T, et al
    Essential childhood immunization in 43 low- and middle-income countries: Analysis of spatial trends and socioeconomic inequalities in vaccine coverage.
    PLoS Med. 2023;20:e1004166.
    >> Share

  5. WAN J, Cazer CL, Clarkberg ME, Henderson SG, et al
    Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    PLoS Med. 2023;20:e1004153.
    >> Share

  6. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2023;20:e1004159.
    >> Share

  7. PORTNOY A, Clark RA, Quaife M, Weerasuriya CK, et al
    The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
    PLoS Med. 2023;20:e1004155.
    >> Share

  8. BOR J, Assoumou SA, Lane K, Diaz Y, et al
    Inequities in COVID-19 vaccine and booster coverage across Massachusetts ZIP codes after the emergence of Omicron: A population-based cross-sectional study.
    PLoS Med. 2023;20:e1004167.
    >> Share

  9. CERQUEIRA-SILVA T, Shah SA, Robertson C, Sanchez M, et al
    Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
    PLoS Med. 2023;20:e1004156.
    >> Share

    December 2022
  10. LIND ML, Robertson AJ, Silva J, Warner F, et al
    Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.
    PLoS Med. 2022;19:e1004136.
    >> Share

    November 2022
  11. BABOUEE FLURY B, Gusewell S, Egger T, Leal O, et al
    Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    PLoS Med. 2022;19:e1004125.
    >> Share

  12. NIELSEN KF, Moustsen-Helms IR, Schelde AB, Gram MA, et al
    Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    PLoS Med. 2022;19:e1004037.
    >> Share

    October 2022
  13. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2022;19:e1003979.
    >> Share

    September 2022
  14. GRAM MA, Emborg HD, Schelde AB, Friis NU, et al
    Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    PLoS Med. 2022;19:e1003992.
    >> Share

    August 2022
  15. MODY A, Bradley C, Redkar S, Fox B, et al
    Quantifying inequities in COVID-19 vaccine distribution over time by social vulnerability, race and ethnicity, and location: A population-level analysis in St. Louis and Kansas City, Missouri.
    PLoS Med. 2022;19:e1004048.
    >> Share

    July 2022
  16. HERNANDEZ I, Dickson S, Tang S, Gabriel N, et al
    Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system-based cross-sectional study.
    PLoS Med. 2022;19:e1004069.
    >> Share

  17. MASSARI M, Spila Alegiani S, Morciano C, Spuri M, et al
    Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    PLoS Med. 2022;19:e1004056.
    >> Share

    June 2022
  18. TAKUVA S, Takalani A, Seocharan I, Yende-Zuma N, et al
    Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    PLoS Med. 2022;19:e1004024.
    >> Share

  19. WONG CKH, Lau KTK, Xiong X, Au ICH, et al
    Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    PLoS Med. 2022;19:e1004018.
    >> Share

    May 2022
  20. JIN P, Guo X, Chen W, Ma S, et al
    Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    PLoS Med. 2022;19:e1003953.
    >> Share

  21. MARTIN CA, Pan D, Melbourne C, Teece L, et al
    Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis.
    PLoS Med. 2022;19:e1004015.
    >> Share

  22. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    Correction: COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2022;19:e1003990.
    >> Share

  23. VAN GILS MJ, Lavell A, van der Straten K, Appelman B, et al
    Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    PLoS Med. 2022;19:e1003991.
    >> Share

  24. QIAN G, Toizumi M, Clifford S, Le LT, et al
    Association of pneumococcal carriage in infants with the risk of carriage among their contacts in Nha Trang, Vietnam: A nested cross-sectional survey.
    PLoS Med. 2022;19:e1004016.
    >> Share

    April 2022
  25. FOO D, Sarna M, Pereira G, Moore HC, et al
    Prenatal influenza vaccination and allergic and autoimmune diseases in childhood: A longitudinal, population-based linked cohort study.
    PLoS Med. 2022;19:e1003963.
    >> Share

  26. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Correction: Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003982.
    >> Share

    March 2022
  27. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003932.
    >> Share

    February 2022
  28. SAAKSVUORI L, Betsch C, Nohynek H, Salo H, et al
    Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial in Finland.
    PLoS Med. 2022;19:e1003919.
    >> Share


  29. Vaccine equity: A fundamental imperative in the fight against COVID-19.
    PLoS Med. 2022;19:e1003948.
    >> Share

  30. KERR S, Joy M, Torabi F, Bedston S, et al
    First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    PLoS Med. 2022;19:e1003927.
    >> Share

  31. WHITELEY WN, Ip S, Cooper JA, Bolton T, et al
    Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    PLoS Med. 2022;19:e1003926.
    >> Share

  32. MCQUAID F, Mulholland R, Sangpang Rai Y, Agrawal U, et al
    Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic: An observational study of routinely collected data.
    PLoS Med. 2022;19:e1003916.
    >> Share

    January 2022
  33. GENTILE I, Schiano Moriello N
    COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination.
    PLoS Med. 2022;19:e1003917.
    >> Share

  34. ANYWAINE Z, Barry H, Anzala O, Mutua G, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
    PLoS Med. 2022;19:e1003865.
    >> Share

    December 2021
  35. GRAM MA, Nielsen J, Schelde AB, Nielsen KF, et al
    Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    PLoS Med. 2021;18:e1003874.
    >> Share

  36. PETERSEN M, Schwab J, Havlir DV
    SARS-CoV-2 vaccine boosters: The time to act is now.
    PLoS Med. 2021;18:e1003882.
    >> Share

    November 2021
  37. MARTIN CA, Marshall C, Patel P, Goss C, et al
    SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study.
    PLoS Med. 2021;18:e1003823.
    >> Share

  38. BHANU C, Gopal DP, Walters K, Chaudhry UAR, et al
    Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review.
    PLoS Med. 2021;18:e1003826.
    >> Share

    October 2021
  39. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2021;18:e1003815.
    >> Share

  40. FORMICA N, Mallory R, Albert G, Robinson M, et al
    Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    PLoS Med. 2021;18:e1003769.
    >> Share

  41. ISANAKA S, Garba S, Plikaytis B, McNeal MM, et al
    Correction: Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial.
    PLoS Med. 2021;18:e1003776.
    >> Share

  42. BARRY H, Mutua G, Kibuuka H, Anywaine Z, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
    PLoS Med. 2021;18:e1003813.
    >> Share

  43. GENG EH, Reid MJA, Goosby E, Abdool-Karim Q, et al
    COVID-19 and global equity for health: The good, the bad, and the wicked.
    PLoS Med. 2021;18:e1003797.
    >> Share

    September 2021
  44. NAGATA JM, Epstein A, Ganson KT, Benmarhnia T, et al
    Drought and child vaccination coverage in 22 countries in sub-Saharan Africa: A retrospective analysis of national survey data from 2011 to 2019.
    PLoS Med. 2021;18:e1003678.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016